The professor of neurology at University of Colorado School of Medicine talked about the challenges of telehealth and device-based data collection in clinical practice. [WATCH TIME: 4 minutes]
Despite advancements in NMOSD treatments, the founder and executive director of the Sumaira Foundation discussed how misdiagnosis, delayed diagnosis, and disparities in care remain significant challenges. [WATCH TIME: 4 minutes]
The professor of neurological sciences at the University of Vermont discussed the work of the MS Differential Diagnosis Consortium, highlighting efforts to refine MS differential diagnosis and improve clinical accuracy. [WATCH TIME: 8 minutes]
The medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed findings from phase 3 trials suggesting that baseline PRLs can predict disability accumulation and may serve as biomarkers for treatment response to tolebrutinib. [WATCH TIME: 6 minutes]
The associate researcher at the University of California, San Francisco discussed a refined EAE model that could better replicate MS pathology, enabling deeper insights into demyelination, neuronal loss, and remyelination. [WATCH TIME: 6 minutes]
The professor of neurology and neurosurgery at McGill University discussed the evolving understanding of neuroimmune interactions in MS, highlighting how these interactions contribute to disease progression and potential repair mechanisms. [WATCH TIME: 4 minutes]
The assistant professor in the department of neurology at Mount Sinai talked about a recent study that highlighted how socioeconomic status and diet could significantly impact physical and cognitive outcomes in patients with MS. [WATCH TIME: 2 minutes]
The professor of neurology at University of Colorado School of Medicine discussed the evolving landscape of MS treatment, highlighting the role of personalized medicine and biomarker-driven decision-making. [WATCH TIME: 5 minutes]
The instructor in the department of radiology at Weill Cornell Medicine discussed how structural and functional brain connectomes can potentially improve predictions of MS progression and treatment response. [WATCH TIME: 4 minutes]
A post-hoc analysis of patients from the CHAMPION-NMOSD trial revealed that the majority received their initial meningococcal vaccination within 6-months of their last rituximab dose.
The professor of neurosurgery and physiology at University of Colorado School of Medicine talked about how vagus nerve stimulation may promote remyelination and functional recovery in multiple sclerosis. [WATCH TIME: 4 minutes]
A late-breaking study presented at the 2025 ACTRIMS Forum reported that a modified Atkins diet reduced inflammation and altered immune cell metabolism in multiple sclerosis.
At the 2025 ACTRIMS Forum, the director of the MS Comprehensive Care Center at Stony Brook Medicine discussed the evolution of high-efficacy treatments for MS. [WATCH TIME: 4 minutes]
Data from more than 16,000 trial participants point to possible challenges with assessing and safely administering novel therapeutics among those with comorbidities—which may be present in as much as half of the patient population.
In the CAVS-MS study, 19% of participants with atypical or radiological-only presentations met the 2024 McDonald Criteria for MS, enabling earlier treatment initiation.
GFAP changes positively correlated with gadolinium-enhancing lesion volume (P = 0.18) and negatively with left ventricular volume (P = -0.19).
The vice president and senior global program lead for Hematology and Cell Therapy at BMS gave clinical commentary on encouraging phase 1 findings of CD19-XT in progressive and relapsing multiple sclerosis.
In both HERCULES and GEMINI trials, tolebrutinib reduced the risk of 6-month confirmed disability worsening, especially in participants with at least 4 baseline paramagnetic rim lesions.
Glatiramer acetate depot treatment showed stability in EDSS scores over 3 years, suggesting halted progression in patients with primary progressive MS.
At the 2025 ACTRIMS Forum, the system chief of neuroimmunology and multiple sclerosis at OhioHealth discussed the need for better tools to detect MS progression. [WATCH TIME: 3 minutes]
The director of the MS and Demyelinating Disease Center at Texas Tech University Health Sciences Center talked about early diagnosis, timely treatment, and minimizing therapy transition gaps to prevent severe disability in patients with NMOSD. [WATCH TIME: 4 minutes]
After 24 months after switching to cladribine, 100% of patients with relapsing MS remained free from T1 gadolinium-enhancing lesions, with no reported cases of PML or rebound disease activity.
The assistant professor of neurology and neurosurgery at McGill University discussed the role of paramagnetic rim lesions as potential biomarkers of compartmentalized inflammation in MS. [WATCH TIME: 4 minutes]
The founder and executive director of the Sumaira Foundation talked about how the landscape of NMOSD treatment has drastically improved with FDA-approved therapies, while noting that accessibility and awareness remain significant challenges. [WATCH TIME: 4 minutes]
The assistant professor of medicine at the University of Toronto talked about emerging research on how prodromal symptoms may aid in the early identification of multiple sclerosis and neuromyelitis optica spectrum disorder. [WATCH TIME: 6 minutes]
The 80 mg QD dosage, which showed the greatest efficacy in lesion reduction (92.3% at 24 weeks), will be used in phase 3 progressive MS studies.
At the 2025 ACTRIMS Forum, the assistant professor of neuroimmunology at McGill University talked about examining immune cell signatures to track disease worsening in multiple sclerosis. [WATCH TIME: 4 minutes]
A new phase 1 study will investigate the safety and biological effects of light therapy as a potential approach to alleviating fatigue in patients with progressive multiple sclerosis.
The autoimmune neurology program director at the University of Colorado highlighted the potential of CAR T-cell therapy for treating autoimmune neurologic diseases like progressive forms of multiple sclerosis. [WATCH TIME: 3 minutes]
The autoimmune neurology program director at the University of Colorado talked about the emerging use of CAR T-cell therapy, a breakthrough from oncology, now being explored in autoimmune neurologic diseases like multiple sclerosis. [WATCH TIME: 3 minutes]
